Dry Powder Media Manufacturing Grand Island Expansion
Take a video tour of our newly expanded dry powder media manufacturing facility in Grand Island, New York. The expansion has added more than 45,000 square feet of Animal Origin Free (AOF) manufacturing space to help meet the increasing global demand for cell culture media. This $76 million investment increases the site’s capacity to produce critical raw materials used in the development and manufacturing of vaccines and biologic therapies. The expansion opened in August 2022 and has added more than 45,000 square feet of Animal Origin Free (AOF) manufacturing space. This includes manufacturing of Thermo Fisher’s Advanced Granulation Technology (AGT) format and other AOF Dry Powder Media (DPM) products. With this expansion, the Grand Island site provides the redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of important medicines, including for COVID-19 vaccines. The Grand Island expansion is part of Thermo Fisher’s $650 million multi-year investment, announced in 2021, to ensure flexible, scalable, and reliable bioprocessing production capacity for its customers.